|Evans Blue tetrasodium salt L-glutamate uptake inhibitor|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||314-13-6||SDF||Download SDF|
|Chemical Name||sodium (6Z,6'Z)-6,6'-(2,2'-(3,3'-dimethyl-[1,1'-biphenyl]-4,4'-diyl)bis(hydrazin-2-yl-1-ylidene))bis(4-amino-5-oxo-5,6-dihydronaphthalene-1,3-disulfonate)|
|Solubility||≥192.4 mg/mL in DMSO, <4.79 mg/mL in EtOH, ≥213.8 mg/mL in H2O||Storage||Store at RT|
|Physical Appearance||A solid||Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
IC50: 220 and 150 nM for GluRl and GIuR6, respectively.
Evans Blue tetrasodium salt is a potent inhibitor of AMPA and kainate receptor-mediated currents (GluRl and GIuR6).
Pharmacologically, the glutamate transporter is specific for glutamate and the closely related analogue L-aspartate does not block the uptake, whereas agents like L-homocysteate and La- aminoadipate block the vesicular L-glutamate uptake poorly.
In vitro: Evans blue inhibits the kainate-mediated responses of the non-NMDA receptor subunits (GIuRl, G1uR1,2, G1uRl,3, and G1uR2,3) expressed in Xenopus oocytes without the response of GluR3 and G1uR6 at low concentrations (IC50= 355 nM for the subunit combination GluR1,2). This pocess was partially reversible without competing with kainate for the agonist binding site . In whole-cell patch clamp recordings of transfected human embryonic kidney 293 cells, Evans blue is a potent inhibitor of glutamate-evoked currents mediated by the kainate-type receptor GIuR6 as long as the AMPA-type receptor GluRl. Interestingly, pretreating with the lectin concanavalin cells recorded relatively little EB inhibition of GIuR6 currents, eliminating kainate receptor desensitization. In addition to decreasing GluR6-mediated peak current amplitude, EB significantly changed receptor desensitization by slowing the rate of onset by ~2-fold (1 M EB) and the rate of recovery by ~2-fold (0.1 p.M EB), and enhancing the steady state to peak current amplitude ratio by ~50-fold (1 M EB) .
In vivo: So far, no study in vivo has been conducted.
Clinical trial: So far, no clinical study has been conducted.
 Roseth S, Fykse EM, Fonnum F. Uptake of L-glutamate into rat brain synaptic vesicles: effect of inhibitors that bind specifically to the glutamate transporter. J Neurochem. 1995 Jul;65(1):96-103.
 Price CJ, Raymond LA. Evans blue antagonizes both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors and modulates receptor desensitization. Mol Pharmacol. 1996 Dec; 50 (6):1665-71.